LEO Pharma Ranks Second in Global Clinical Trials Transparency Audit

Food and Healthcare Press Releases Monday July 31, 2017 08:15
BALLERUP, Denmark and HURLEY, England--31 Jul--PRNewswire/InfoQuest
New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information
(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )
The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry.

LEO Pharma is ranked at number two out of the 50 pharmaceutical companies evaluated. AllTrials is an international campaign that calls for every clinical trial, past and present, to be registered and their results reported. The rankings assess companies' policy commitments on disclosing trial registrations, summary findings of studies, comprehensive clinical study reports (CSRs) and individual patient data (IPD).

As one of the companies in the forefront of data transparency LEO Pharma was early off the mark to globally commit to increased disclosure. Since making this commitment in 2013, LEO Pharma has made its clinical trials results dating back to 1990 available to the public and will share individual patient-level data upon request from qualified third-party researchers. The company's commitment to transparency and patient focus has also evolved with the completion of an innovative project to develop lay summaries for patients and interested parties in easy to understand language.

Commenting on the publication from AllTrials, Katherine Murphy, former CEO of The Patients Association (now Independent Care Consultant) said:

"I very much welcome these audit findings and greater transparency in clinical trials, as well as research and development generally. It is really pleasing to see more information on clinical trials becoming increasingly available in the public domain with companies like LEO Pharma amongst the leaders. The more information that patients and members of the public have will support them to become better placed to make informed decisions and treatment choices."

Kim Kjoeller, Executive Vice President Global Research and Development, LEO Pharma, said:

"The AllTrials rankings are a robust overview which, while grounded in empirical data, casts new light on the attitudes and approaches to transparency across our industry. LEO Pharma welcomes the AllTrials audit and we are delighted to see this positive recognition for our commitment to making our scientific evidence base freely available for scrutiny and study. Having just entered the biologics arena LEO Pharma is at a turning point in our company's history, and we are excited by the promise that our pipeline holds. Maintaining this commitment to openly sharing our vision through timely disclosure of trial information has never been more important to us, and we look forward to continuing to partner with the scientific community to drive the clinical trial transparency agenda to the next level."

For more information on LEO Pharma's commitment to transparency, please see the company's Position on Public Access to Clinical Trials Information at http://www.leo-pharma.com .
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, the company supports people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products and solutions to people suffering from skin diseases.
LEO Pharma is globally headquartered in Denmark and employs around 4,800 people worldwide.
Contact:
Global Media Enquiries
Henrik Kyndlev
Corporate Communications Manager
+45-3140-6180
Henrik.kyndlev@leo-pharma.com
UK and Ireland Media Enquiries
Charlotte Murrain
Communications Manager
+44(0)7557-436-771
charlotte.murrain@leo-pharma.com
Julie Wong
Head of Communications
+44(0)7825-918-989
julie.wong@leo-pharma.com
Source: LEO Pharma A/S

Latest Press Release

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

Related Topics